Clinical trials: Prostate Cancer Detection
Prostate Cancer
BR55 in Prostate Cancer: an Exploratory Clinical Trial
The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging.
- Trial name
- NCT01253213
- Testing
- BR55
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Bracco Diagnostics, Inc
Prostate Cancer
MyProstateScore Equivalency With and Without DRE
The purpose of the study is to quantify the concordance of MPS results between first-catch urine samples collected post-DRE and those collected without a DRE.
- Trial name
- NCT05700370
- Testing
- MyProstateScore
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- LynxDx
Prostate Cancer Detection
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent, up to 20 mL of whole blood will be collected from each subject.
- Trial name
- PRIME (NCT07543757)
- Testing
- Proclarix
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Sequenom, Inc.
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Cancer of Prostate
Investigation of Three Biomarkers for the Detection of Prostate Cancer
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies.
- Trial name
- NCT06554587
- Testing
- Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Medtechtomarket Consulting Ltd
Prostate Cancer
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer.
- Trial name
- NCT00391690
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Novartis
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Prostate Cancer, 18F- Fluorocholine
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
The present study in patients with Prostate cancer and biochemical failure after surgery and/or radical-postoperative Radio Therapy (RT) will evaluate if PET/CT with 18F-JK-PSMA-7 compared to PET-CT 18F-Choline is able to…
- Conditions
- Prostate Cancer, 18F- Fluorocholine, PSMA PET, Radiotherapy
- Trial name
- MIP7 (NCT05622162)
- Testing
- Radiopharmaceutical 18F-JK-PSMA-7, Radiopharmaceutical 18F-Fluorocholine
- Where
- 2 sites in Italy
- Volunteers
- 106 people
- Sponsor
- ITEL Telecomunicazioni Srl
Prostate Cancer, Prostate Cancer Recurrent
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04102553
- Testing
- F-18-PSMA-1007, F-18-Fluorocholine
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Prostate Cancer, Neoplasm, Residual
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
The primary objective of this feasibility study is to determine if administration of LUM015 will result in positive fluorescence of tumor tissue from ex vivo specimen imaging with the LUM Imaging device from patients undergoing…
- Trial name
- NCT03441464
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lumicell, Inc.
Metastatic Castrate Resistant Prostate Cancer
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide)
- Trial name
- NCT03236688
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Prostate Cancer
Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)
Study design: -The study will be a phase I like study to assess the extent to which prostate HistoScanning (PHS, the index test) can identify and characterize foci of prostate cancer when compared to histological samples…
- Trial name
- PHS-02 (NCT01191931)
- Where
- 7 sites in Belgium, Czechia and 3 more
- Volunteers
- 52 people
- Sponsor
- Advanced Medical Diagnostics s.a.
Prostate Cancer
A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy
he most common method for performing a prostate biopsy procedure is the ultrasound guided transrectal procedure. The information obtained from the standard prostate biopsy is deficient and even misleading.
- Trial name
- NaSBxP01 (NCT01480375)
- Testing
- Smartbx™ system.
- Where
- Israel
- Volunteers
- 524 people
- Sponsor
- UC Care, Ltd.
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
The purpose of this study was to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT).
- Trial name
- GuideView (NCT04838626)
- Testing
- [18F]CTT1057
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
This study is to evaluate diagnostic performance, safety and timing of post-dose imaging of ONM-100, an intraoperative fluorescence imaging agent for the detection of cancer in patients with solid tumors undergoing routine…
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03735680
- Testing
- ONM-100
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoNano Medicine, Inc.
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG
Prostate Cancer
EMBRACE1: Prostate Biorepository
The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for…
- Trial name
- NCT01499381
- Where
- United States
- Volunteers
- 1,290 people
- Sponsor
- Caris Science, Inc.
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Prostate Cancer
SonoVue Guided Prostate Biopsy
This is a phase III European multicenter, open label, prospective study to assess the diagnostic accuracy of the use of SonoVue contrast agent to guide prostate biopsies in comparison with the current practice of ultrasound…
- Trial name
- NCT00911027
- Testing
- Contrast-enhanced ultrasound guided biopsy, ultrasound guided systematic biopsy
- Where
- 17 sites in Austria, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- Bracco Diagnostics, Inc